Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

Litchlab Empowers Dual-Drug Liposomal Delivery: A CDMO Engine for Next-Gen Combination Therapies

As the global pharmaceutical industry increasingly pivots toward multi-target interventions and combination strategies, dual-drug co-encapsulated liposomes are emerging as a transformative solution to overcome the limitations of monotherapies. Leveraging a dec...

Litchlab Advances Actively Targeted Liposome Drug Delivery for Precision Oncology and Beyond

Litchlab, a global provider of next-generation nanomedicine delivery platforms, is accelerating the advancement of its Actively Targeted Liposome (ATL) technology to address the growing demand for precision drug delivery in oncology and other complex therapeut...

Litchlab Advances Oncology with Next-Generation Liposomal Drug Delivery Platforms

As the global pharmaceutical industry increasingly pivots towards precision therapeutics, liposomal drug delivery systems are emerging as a transformative force in oncology. Litchlab, a pioneering contract development and manufacturing organization (CDMO), is ...

Litchlab Expands Albumin Nanoparticle Drug Delivery Platform to Address Global Demand for Precision Therapeutics

Litchlab, a global CDMO and technology innovator in next-generation drug delivery, today announced significant advancements in its albumin nanoparticle (ANP) platform technology, expanding its applications to include nucleic acid drugs, chemotherapeutics, and ...

Litchlab Expands Microsphere Drug Delivery Platform to Drive Long-Acting and Targeted Therapies Across Modalities

As the global pharmaceutical landscape accelerates its shift toward intelligent and multifunctional drug delivery systems, Litchlab is strengthening its microsphere-based delivery platform to meet the growing demand for controlled-release, long-acting, and tis...

Litchlab Expands Smart Hydrogel Platform to Enable Next-Generation Programmable Drug Delivery and Tissue Engineering

Litchlab, a global CDMO innovator in advanced drug delivery systems, announces a strategic expansion of its hydrogel-based delivery and biomaterials platform. Engineered for multi-modal encapsulation and intelligent release of proteins, nucleic acids, cytokine...

上一页 1 2 3 4 5 下一页